ULIPRISTAL ACETATE for PMDD
Ulipristal acetate is a Phase 2 clinical candidate for PMDD acting as a progesterone receptor modulator on the progesterone receptor per Open Targets.
Hypothesized mechanism
By modulating the progesterone receptor, ulipristal acetate may blunt the abnormal progesterone-related signaling thought to drive PMDD symptoms.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 6 of 10 overall, a moderate reading, from a pathway rated moderate in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population). (band F1, ×1.00).
Corroboration
Only a single line of evidence is present: an Open Targets database entry noting ULIPRISTAL ACETATE as a Phase 2 candidate for PMDD acting via progesterone receptor modulation. No independent mechanistic studies converge here.
Rigor
The claim derives from a curated drug-target database (Open Targets) indicating Phase 2 clinical staging, which implies human-relevant development, but no actual study design, data, or model is described. This is a registry annotation rather than experimental rigor.
Specificity
The mechanism is explicitly a progesterone receptor modulator acting on the progesterone receptor, a well-defined single named target. The claim directly names the drug's specific action on that target.
Plausibility
PMDD is mechanistically linked to abnormal sensitivity to progesterone/allopregnanolone fluctuations, so a progesterone receptor modulator targeting the progesterone receptor is a strong target-phenotype fit. The claim's named target aligns with the recognized pathophysiology of PMDD.
Consistency
Only one signal is present, so there is no opportunity for multiple mechanistic signals to agree or disagree. The single entry is internally coherent but cannot demonstrate consistency across lines.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Per Open Targets (retrieved 2026-06-16), ULIPRISTAL ACETATE (a Small molecule) is a clinical candidate for PMDD (maximum clinical stage PHASE_2); its mechanism of action is Progesterone receptor modulator on target progesterone receptor. Open Targets · mechanistic ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →